{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:14:01Z","timestamp":1773101641374,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}],"id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.oret.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T08:02:18Z","timestamp":1668153738000},"page":"354-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravitreal Carboplatin as Salvage Treatment for Progressive Vitreous Disease in Retinoblastoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Benjamin A.","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Kaluzny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Overbey-Canon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-4395","authenticated-orcid":false,"given":"Rachel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2022.11.003_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3928\/01913913-20160719-04","article-title":"Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era","volume":"53","author":"Shields","year":"2016","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oret.2022.11.003_bib2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.ophtha.2017.04.010","article-title":"Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.11.003_bib3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaophthalmol.2017.4600","article-title":"Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy","volume":"135","author":"Francis","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib4","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaophthalmol.2014.2324","article-title":"Stability of melphalan solution for intravitreal injection for retinoblastoma","volume":"132","author":"Buitrago","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","article-title":"Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study","volume":"121","author":"Francis","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.11.003_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2022.11.003_bib7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.11.003_bib8","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-05-0849","article-title":"Topotecan combination chemotherapy in two new rodent models of retinoblastoma","volume":"11","author":"Laurie","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oret.2022.11.003_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.2016.69.2996","article-title":"Ocular salvage and vision preservation using a topotecan-based regimen for advanced intraocular retinoblastoma","volume":"35","author":"Brennan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.oret.2022.11.003_bib10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archopht.121.8.1120","article-title":"Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma","volume":"121","author":"Mulvihill","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib11","first-page":"1892","article-title":"Local carboplatin therapy in transgenic murine retinoblastoma","volume":"37","author":"Harbour","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.11.003_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ceo.13711","article-title":"Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma","volume":"48","author":"Lema\u00eetre","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3928\/23258160-20170130-09","article-title":"Preclinical acute ocular safety study of combined intravitreal carboplatin and etoposide phosphate for retinoblastoma","volume":"48","author":"Mohney","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2022.11.003_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5507\/bp.2012.106","article-title":"Retinal toxicity after repeated intravitreal carboplatin injection into rabbit eyes","volume":"158","author":"Pochop","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.oret.2022.11.003_bib15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bjophthalmol-2011-300829","article-title":"Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds","volume":"96","author":"Smith","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ohc.2004.11.003","article-title":"Intraocular retinoblastoma: the case for a new group classification","volume":"18","author":"Murphree","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.oret.2022.11.003_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncr.25574","article-title":"Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma","volume":"117","author":"Nemeth","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.oret.2022.11.003_bib18","first-page":"37","article-title":"Structure, function, and age-related changes of the human vitreous","volume":"223","author":"Sebag","year":"1987","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","article-title":"Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results","volume":"132","author":"Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.11.003_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1089\/jop.2014.0051","article-title":"What do we know about intraocular carboplatin?","volume":"30","author":"Kang","year":"2014","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.oret.2022.11.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100884","article-title":"Paracentral acute middle maculopathy and the organization of the retinal capillary plexuses","volume":"81","author":"Scharf","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2022.11.003_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.oret.2022.11.003_bib23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","article-title":"Understanding platinum-induced ototoxicity","volume":"34","author":"Langer","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.oret.2022.11.003_bib24","first-page":"483","article-title":"Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity","volume":"34","author":"Cavaletti","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.oret.2022.11.003_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2004.09.013","article-title":"Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in\u00a0vitro and in\u00a0vivo: a potential mechanism for neurotoxicity","volume":"18","author":"McDonald","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.oret.2022.11.003_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.heares.2006.09.015","article-title":"Mechanisms of cisplatin-induced ototoxicity and prevention","volume":"226","author":"Rybak","year":"2007","journal-title":"Hear Res"},{"key":"10.1016\/j.oret.2022.11.003_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/09273948.2015.1071404","article-title":"Localization of human copper transporter 1 in the eye and its role in eales disease","volume":"24","author":"Narayanan","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oret.2022.11.003_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13816810.2014.973045","article-title":"Classification and management of seeds in RB. Ellsworth Lecture Ghent 8\/24\/2013","volume":"35","author":"Munier","year":"2014","journal-title":"Ophthalmic Genet"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022005516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022005516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:32:01Z","timestamp":1762853521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653022005516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2468653022005516"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2022.11.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Carboplatin as Salvage Treatment for Progressive Vitreous Disease in Retinoblastoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}